On March 18, 2021 Amplia Therapeutics (ATX) reported that it has signed a term sheet for a collaboration agreement with the Garvan Institute of Media Research in Sydney (Press release, Amplia Therapeutics, MAR 18, 2021, View Source;[email protected] [SID1234576887]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The term sheet maps out a collaborative research and clinical development program, focused on the use of Amplia’s FAK inhibitor, AMP945, to treat patients with pancreatic cancer.

The collaboration will initially look at new treatment regiments and patient selection strategies for Amplia’s clinical trials of AMP945 in pancreatic cancer patients later this year.

The collaboration will combine the Garvan Institute’s research strength in FAK biology and its extensive clinical research network with Amplia’s proprietary FAK inhibitors and drug development capability.

"The purpose of this collaboration is to optimise our planned clinical program for AMP945," said Amplia’s CEO and Managing Director, Dr John Lambert.

"Clearly, Garvan’s team has an unsurpassed understanding of FAK biology and access to an extensive clinical network. By leveraging Garvan’s deep understanding of the different biological roles that FAK can play, we aim to optimise the design of our planned clinical trials, recruit the right pancreatic cancer patients and treat them in the right way, giving AMP945 the best chance for success."

Professor Paul Timpson, Cancer Research Theme Leader at Garvan will be the lead scientist in the collaborative research program, after collaborating with Amplia for over a year.

The terms of the agreement are confidential but include future payments by Amplia to Garvan based on AMP945 achieving specified clinical, regulatory and commercial sales milestones.

The final Collaboration Agreement is expected to be signed within 90 days. While the terms of the agreement are confidential, they do include future, success-based payments by Amplia to Garvan on AMP945 achieving specified clinical, regulatory and commercial sales milestones.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics